Rare genetic cause of peritoneal mesothelioma points to targeted therapy

September 14, 2017
Immunohistochemistry for ALK in peritoneal mesothelioma shows separation of the 5' (green) and 3' (red) probe signals in each of the 3 cases with diffuse strong ALK expression, indicating bona fide ALK rearrangement Credit: JAMA Network copyright 2017 American Medical Association

Mesothelioma is a rare and aggressive tumor that, in many cases, results from exposure to asbestos. But over the last several decades, other causes of the disease have emerged, including treatment with high-intensity therapeutic radiation and, more recently, an inherited genetic mutation. Now, through an unexpected observation and a meticulous study of patients seen at Brigham and Women's Hospital, BWH investigators have added a fourth cause to the list: a genetic rearrangement in the ALK gene, observed in three patients with peritoneal mesothelioma. Unlike previously known causes, this new discovery points to a potential therapeutic approach for those few patients whose tumors harbor the mutation.

The team's findings are published in JAMA Oncology.

"Mesothelioma is highly lethal and has no cure. Often, it is not diagnosed until at a late stage, when many tumors have already formed," said principal investigator Lucian Chirieac, MD, a thoracic oncology pathologist in the Department of Pathology at BWH and associate professor at Harvard Medical School. "Although this mutation only exists in a small percentage of cases, this discovery points to a potential therapeutic avenue for these patients."

There are about 3,000 new cases of mesothelioma each year in the U.S., and only about 300 of those are peritoneal mesothelioma, which forms in the lining of the abdomen. Most cases of mesothelioma result decades after exposure to asbestos or radiation therapy. But in rare cases, young patients who have never been exposed to either risk factor are diagnosed with the disease. One such case led Chirieac and his colleagues to their unexpected finding.

"This was a serendipitous discovery. We had a young patient with peritoneal mesothelioma that was difficult to diagnose. We extended our molecular diagnostics to test for a genetic rearrangement that had been reported in lymphoma and , but never in mesothelioma. When it came back positive, we were intrigued," said first author Yin (Rex) Hung, MD, PhD, the Corson Thoracic Pathology Fellow in the Department of Pathology at BWH and HMS.

Hung and Chirieac collaborated with other physicians and scientists at BWH and Massachusetts General Hospital to confirm their observation. They carefully examined samples from 88 consecutive patients with peritoneal mesothelioma who had been seen at BWH between 2005 and 2015. They identified ALK-positive mesotheliomas by immunohistochemistry; confirmed with fluorescence in situ hybridization; and performed targeted next-generation sequencing of tumor DNA and RNA to get a full picture of the exact genetic rearrangement underpinning the disease.

Three patient samples were positive for ALK—these patients with peritoneal mesothelioma were women with no history of asbestos or radiation therapy exposure. They also looked in samples collected from patients with pleural mesothelioma—the more common form of the diseases—but none of those samples were positive for ALK.

The ALK gene is important during embryonic development of the nervous system but should be inactive later in life. Previous studies of genetic alterations in lymphoma and lung cancer have found that certain genetic mutations—specifically when part of a gene breaks off and gets fused to another—can inappropriately switch on ALK, driving cancer cells to grow and divide. Targeting ALK with therapeutic drugs can turn that switch back off, blocking cancer progression—at least temporarily - without harming healthy cells. The FDA has approved several ALK inhibitors for treating non-small cell lung cancer. While the costs of targeted therapy may remain high, the cost of diagnostic testing for such genetic rearrangements is low.

Chirieac and colleagues hope to extend their study of ALK-positive mesotheliomas in a global patient population. In his own practice, Chirieac is routinely examining for the presence of ALK rearrangements for with mesothelioma and educating his residents about this new finding."When I teach my residents about the causes of , I talk to them about asbestos, and an inherited mutation," said Chirieac. "We believe this paper adds a fourth cause to that list - one that is potentially clinically actionable."

Explore further: Study examines association of asbestos exposure, mesothelioma in Eastern China

More information: JAMA Oncology (2017). DOI: 10.1001/jamaoncol.2017.2918

Related Stories

Study examines association of asbestos exposure, mesothelioma in Eastern China

December 1, 2016
A new research letter published online by JAMA Oncology looks at asbestos exposure and malignant mesothelioma in Eastern China.

New genetic insights into mesothelioma

February 29, 2016
Mesothelioma is a rare but deadly form of cancer: the five-year survival rate for patients diagnosed with the disease is between five and ten percent. Although aggressive surgery can help some patients with early-stage mesothelioma, ...

Study of potential new treatment for mesothelioma open to patients

September 15, 2016
The Baylor College of Medicine Mesothelioma Treatment Center at Baylor St. Luke's Medical Center has begun enrolling patients in a clinical research study looking at an investigational drug in patients with malignant pleural ...

Mesothelioma risk endures over long-term

September 22, 2014
Western Australian researchers have determined the risk of developing mesothelioma continues to increase even 40 years after a person's first exposure to asbestos.

Early research suggests first immunotherapy for mesothelioma on the horizon

June 5, 2017
Malignant pleural mesothelioma or MPM is a rare cancer, but its incidence has been rising. This cancer is usually associated with asbestos exposure, and patients have a median life expectancy of only 13-15 months. All patients ...

Researchers find potential new target to treat malignant pleural mesothelioma

July 25, 2013
Malignant mesothelioma is a rare asbestos-associated malignancy with limited therapeutic options. Despite advances in the treatment, the median survival remains 12 months from the time of diagnosis. Increased understanding ...

Recommended for you

Researchers unravel novel mechanism by which tumors grow resistant to radiotherapy

November 23, 2017
A Ludwig Cancer Research study has uncovered a key mechanism by which tumors develop resistance to radiation therapy and shown how such resistance might be overcome with drugs that are currently under development. The discovery ...

African Americans face highest risk for multiple myeloma yet underrepresented in research

November 23, 2017
Though African-American men are three times more likely to be diagnosed with multiple myeloma, a type of blood cancer, most scientific research on the disease has been based on people of European descent, according to a study ...

Encouraging oxygen's assault on iron may offer new way to kill lung cancer cells

November 22, 2017
Blocking the action of a key protein frees oxygen to damage iron-dependent proteins in lung and breast cancer cells, slowing their growth and making them easier to kill. This is the implication of a study led by researchers ...

One-size treatment for blood cancer probably doesn't fit all, researchers say

November 22, 2017
Though African-American men are three times more likely to be diagnosed with a blood cancer called multiple myeloma, most scientific research on the disease has been based on people of European descent, according to a study ...

One in four U.S. seniors with cancer has had it before

November 22, 2017
(HealthDay)—For a quarter of American seniors, a cancer diagnosis signals the return of an old foe, new research shows.

Combination immunotherapy targets cancer resistance

November 22, 2017
Cancer immunotherapy drugs have had notable but limited success because in many cases, tumors develop resistance to treatment. But researchers at Yale and Stanford have identified an experimental antibody that overcomes this ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.